Difference between revisions of "Voxelotor (Oxbryta)"
Jump to navigation
Jump to search
m |
m |
||
| Line 17: | Line 17: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Hemoglobin S polymerization inhibitors]] | ||
| + | |||
[[Category:Sickle cell anemia medications]] | [[Category:Sickle cell anemia medications]] | ||
[[Category:EMA approved in 2022]] | [[Category:EMA approved in 2022]] | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
Revision as of 12:43, 23 September 2023
Mechanism of action
hemoglobin S polymerization inhibitor
Diseases for which it is used
History of changes in FDA indication
- 2019-11-25: Granted accelerated approval for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.
History of changes in EMA indication
- 2022-02-14: Initial EMA authorization
Also known as
- Code names: GBT-440, GTx-011
- Brand name: Oxbryta